Price Alert

Madrigal Pharmaceuticals ... (MDGL)

NASDAQ: MDGL · Real-Time Price · USD

370.89

-2.57 (-0.69%)

At close: Aug 14, 2025, 3:59 PM

371.01

0.03%

After-hours: Aug 14, 2025, 07:38 PM EDT

-0.69% (1D)

Bid	330
Market Cap	8.27B
Revenue (ttm)	515.55M
Net Income (ttm)	-281.9M
EPS (ttm)	-12.64
PE Ratio (ttm)	-29.34
Forward PE	63.76
Analyst	Strong Buy

Ask	399.6
Volume	293,588
Avg. Volume (20D)	356,737
Open	370.56
Previous Close	373.46
Day's Range	368.10 - 375.67
52-Week Range	200.63 - 377.46
Beta	-1.03

About MDGL

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MDGL

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MDGL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Madrigal Pharmaceuticals has released their quartely earnings on Aug 5, 2025:

Revenue of $212.8M exceeds estimates by $51.48M, with 1353.76% YoY growth.

EPS of -1.9 exceeds estimates by 1.62, with 73.24% YoY growth.

Next Earnings Release

Madrigal Pharmaceuticals Inc. is scheduled to release its earnings on Oct 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+8.59%

Madrigal Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription

1 month ago

+10.87%

Madrigal Pharmaceuticals shares are trading higher after the company received a Notice of Allowance from the US Patent and Trademark Office for a new patent covering Rezdiffra.

News

1 week ago · youtube.com

Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

Bill Sibold, Madrigal Pharmaceuticals CEO, joins 'Fast Money' to discuss Q2 earnings results, the weight loss space and their GLP-1 strategy.

1 week ago · seekingalpha.com

Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Soergel - Executive VP & Chief Medical Officer Mardi C. Dier - Execu...

1 week ago · zacks.com

Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates

Madrigal (MDGL) came out with a quarterly loss of $1.9 per share versus the Zacks Consensus Estimate of a loss of $3.48. This compares to a loss of $7.1 per share a year ago.

2 weeks ago · seekingalpha.com

Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term

Madrigal Pharmaceuticals, Inc.'s Rezdiffra showed strong Q1 2025 sales of $137.3M that highlight robust U.S. demand and early commercial momentum in non-cirrhotic NASH patients. Key catalysts include ...

4 weeks ago · zacks.com

MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights

Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.

4 weeks ago · zacks.com

Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?

Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

1 month ago · marketwatch.com

Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease nonci...

3 months ago · seekingalpha.com

In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals

Madrigal Pharmaceuticals' Rezdiffra for NASH achieved $137.3M in Q1 '25 sales, surpassing analyst estimates and indicating strong growth, but the stock hasn't rallied. Near-term catalysts include pote...